Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy

Hsing-Wu Chen,Yao-Wen Kuo,Chung-Yu Chen,Chin-Hao Chang,Su-Mei Wang,Ying-Chun Chien,Wei-Chen Lu,Jo-Pai Chen,Cheng-Yu Chang,Yu-Feng Wei,Shih-Chieh Chang,Chin-Chung Shu,Jann-Yuan Wang,Wei-Yu Liao,Hao-Chien Wang,Chong-Jen Yu
DOI: https://doi.org/10.1093/oncolo/oyad340
2024-01-16
The Oncologist
Abstract:Abstract Objective Reports of tuberculosis (TB) during anticancer treatment with immune checkpoint inhibitors (ICIs) are increasing. However, it is not clear whether the use of ICIs is a significant risk factor for TB, including reactivation or latent TB infection (LTBI). Methods To determine the risk of TB reactivation in patients with lung cancer who use ICIs or tyrosine kinase inhibitors (TKIs), we conducted a retrospective study using a hospital-based cancer registry. In addition, we monitored patients with cancer using ICI or TKI in a multicenter prospective study to check the incidence of LTBI. Results In the retrospective study, several demographic factors were imbalanced between the ICI and TKI groups: the ICI group was younger, had more males, exhibited more squamous cell carcinoma in histology rather than adenocarcinoma, had fewer EGFR mutations, and received more chemotherapy. Propensity score matching was used to control for confounding factors, and we found that the incidence of TB was higher among patients with lung cancer who received ICIs than among those who received TKIs (2298 vs 412 per 100 000 person-years, P = .0165). Through multivariable analysis, group (ICI vs TKI) was the independent risk factor for TB development (adjusted hazard ratio (aHR): 6.29, 95% CI, 1.23-32.09, P = .0269). In the prospective cohort, which included 72 patients receiving ICIs and 50 receiving TKIs, we found that the incidence of positive seroconversion of LTBI by interferon gamma release assay (IGRA) was significantly higher in patients receiving ICIs (18% vs 0%, aHR: 9.88, P = 0.035) under multivariable Cox regression. Conclusion The use of ICIs may be linked to a higher likelihood of TB reactivation and LTBI than individuals solely receiving TKIs as anticancer therapy. Consequently, the implementation of a screening program for TB reactivation and LTBI among patients undergoing ICI treatment could prove advantageous by enabling early detection and prompt treatment of the infection.
oncology
What problem does this paper attempt to address?
### What problem does this paper attempt to solve? This paper aims to explore whether immune checkpoint inhibitors (ICIs) increase the risk of tuberculosis (TB) re - activation or latent tuberculosis infection (LTBI) in cancer patients, especially those with lung cancer. Specifically, the study answers this question through the following two aspects: 1. **Retrospective Cohort Study**: - Researchers retrospectively analyzed cancer registration data in hospitals and compared the TB re - activation risk between lung cancer patients receiving ICIs treatment and those receiving tyrosine kinase inhibitors (TKIs) treatment. - Propensity score matching was used to control confounding factors and ensure comparability between the two groups. 2. **Prospective Cohort Study**: - Researchers conducted a prospective study in multiple teaching hospitals to monitor the LTBI seroconversion in pan - cancer patients receiving ICIs and TKIs treatment. - The LTBI status of patients was regularly detected by interferon - gamma release assay (IGRA) to evaluate the impact of ICIs on LTBI. ### Main Findings - **Results of Retrospective Study**: - After adjusting for potential confounding factors, the incidence of TB re - activation in lung cancer patients receiving ICIs treatment was significantly higher than that in patients receiving TKIs treatment (2298 vs 412 per 100,000 person - years, P =.0165). - Multivariate Cox proportional - hazards regression analysis showed that the ICIs group was an independent risk factor for TB development (adjusted hazard ratio: 6.29, 95% CI: 1.23 - 32.09, P =.0269). - **Results of Prospective Study**: - In the prospective cohort, the LTBI seroconversion rate was 18% in patients receiving ICIs treatment, while it was 0% in patients receiving TKIs treatment (adjusted hazard ratio: 9.88, P = 0.035). ### Conclusion This study indicates that the use of ICIs may increase the risk of TB re - activation and LTBI in lung cancer patients. Therefore, screening patients for TB re - activation and LTBI before starting ICIs treatment may be beneficial, which can enable early detection and timely treatment of infections. ### Keywords - Tuberculosis - Latent Tuberculosis Infection - Immune Checkpoint Inhibitors ### Summary This paper systematically evaluated the impact of ICIs on TB re - activation and LTBI through retrospective and prospective studies, providing important clinical guidance significance and emphasizing the importance of TB screening before ICIs treatment.